![Budesonide Is Effective in Adolescent and Adult Patients with Active Eosinophilic Esophagitis Budesonide Is Effective in Adolescent and Adult Patients with Active Eosinophilic Esophagitis](http://web.archive.org./web/20110907174723im_/http://i.ytimg.com/vi/8SokB_6pDAk/0.jpg)
- Order:
- Duration: 5:11
- Published: 21 Oct 2010
- Uploaded: 01 Nov 2010
- Author: AmerGastroAssn
It is marketed by AstraZeneca as a nasal inhalant under the brand name Rhinocort (in Denmark, as Rhinosol), as an oral inhalant under the brand name Pulmicort (in Israel, Budicort), and as either an enema or a modified-release oral capsule under the brand name Entocort. It is also sold in combination with formoterol (Oxis) in a single inhaler, under the brand name Symbicort. In Brazil it is marketed by Eurofarma under the brand name Noex. Entocort EC is an oral capsule marketed in the United States by Prometheus Laboratories. Entocort is an expensive drug, costing between 800US and 1500US.
A new formulation is in clinical trials for ulcerative colitis.
Budesonide in comparison with prednisolone has been associated with fewer bone density losses, and, unlike other corticosteroids, has little influence on the hypothalamic-pituitary-adrenal axis, which also limits the need of tapering before discontinuation. Overall, it has a lower incidence of systemic manifestations than similar medications.
In addition, the following symptoms should be reported immediately:
Unlike OTC nasal decongestants, budesonide has not been shown to cause rebound nasal congestion.
Category:Glucocorticoids Category:Asthma Category:AstraZeneca
This text is licensed under the Creative Commons CC-BY-SA License. This text was originally published on Wikipedia and was developed by the Wikipedia community.